Health Care • Biotechnology: Pharmaceutical Preparations
$13.65 ▼ -0.50
(-3.53%)
MKT CAP: $1.26B • VOL: 2.54M
52W L $13 52W H $26
SNDX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $172.4M | $23.7M | $0 |
| YoY Revenue Growth % | +627.8% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$273.1M | -$339.7M | -$230.0M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$285.4M | -$318.8M | -$209.4M |
| EBITDA (Normalized) | -$272.9M | -$339.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$323.0M | -$274.9M | -$160.6M |
| Capital Expenditures (CapEx) | $187.0K | $0 | — |
| Free Cash Flow (FCF) | -$323.2M | -$274.9M | -$160.6M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $134.9M | $154.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $64.6M | $288.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SNDX.